Broadcom (AVGO) Declares $0.59 Quarterly Dividend; 0.9% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/9/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Broadcom Limited (AVGO) PT Raised to $295 at Truist Securities, 'Buy the near-term weakness'
June 6, 2025 7:06 AM EDTTruist Securities analyst William Stein raised the price target on Broadcom Limited (NASDAQ: AVGO) to $295.00 (from $267.00) while maintaining a Buy rating.
The analyst comments "Buy the near-term weakness. AVGO posted very modest upside to CQ1 (Apr) results, and CQ2 (July) guidance.... More
Broadcom Limited (AVGO) PT Raised to $325 at JPMorgan
June 6, 2025 5:16 AM EDTJPMorgan analyst Harlan Sur raised the price target on Broadcom Limited (NASDAQ: AVGO) to $325.00 (from $250.00) while maintaining a Overweight rating.
The analyst comments "We see the recent ruling from the U.S. District Court for the District of Delaware in favor of ACAD regarding its 721 formulation patent for Nuplazid (pimavanserin) on both infringement and validity arguments against Aurobindo Pharma and other ANDA filers (see document here) as a clear positive. Note that the 721 patent provides protection for the Nuplazid 34mg capsule formulation into 2038. We believe it is logical to assume the parties... More
Broadcom Limited (AVGO) PT Raised to $270 at Morgan Stanley
June 6, 2025 4:59 AM EDTMorgan Stanley analyst Joseph Moore raised the price target on Broadcom Limited (NASDAQ: AVGO) to $270.00 (from $260.00) while maintaining a Overweight rating.
The analyst comments "Thoughts on the stock: AVGO seems the most uncontroversial of the AI names ever since the 2027 SAM raised longer term expectations. That makes sense... More
Broadcom Limited (AVGO) PT Raised to $304 at Evercore ISI, 'We’re Still Buyers'
June 6, 2025 4:54 AM EDTEvercore ISI analyst Mark Lipacis raised the price target on Broadcom Limited (NASDAQ: AVGO) to $304.00 (from $267.00) while maintaining a Outperform rating.
The analyst comments "Were Still Buyers of AVGO after an in-line AprQ print and implied EPS outlook that is $0.01 below consensus. AI revs... More
Broadcom Limited (AVGO) PT Raised to $315 at KeyBanc
June 6, 2025 4:49 AM EDTKeyBanc analyst John Vinh raised the price target on Broadcom Limited (NASDAQ: AVGO) to $315.00 (from $275.00) while maintaining a Overweight rating.
The analyst comments "AVGO reported solid F2Q (Apr) results and provided mixed F3Q (Jul) guidance (higher revs, lower... More
